FDA Approves New Drug for Advanced Breast Cancer Subtype

The U.S. Food and Drug Administration has granted approval for vepdegestrant, a new medication targeting a specific form of advanced or metastatic breast cancer. This treatment is intended for patients whose disease has progressed after initial endocrine therapy and who have particular genetic mutations. A companion diagnostic test was also approved to identify eligible patients, with clinical trials indicating improved progression-free survival for those receiving the drug.